NuCana PLC
NCNA0.660USD
0.000
Fechamento 04/24, 16:00（ET）Cotações atrasadas em 15 min
3.75MValor de mercado
PerdaP/L TTM
Informações de NuCana PLC Empresa
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.
Informações da empresa
Código da empresaNCNA
Nome da EmpresaNuCana PLC
Data de listagemSep 28, 2017
Fundado em1997
CEOMr. Hugh S. Griffith
Funcionários20
Tipo de TítulosDepository Receipt
Fim do ano fiscalSep 28
EndereçoLochside House
CidadeEDINBURGH
Bolsa de ValoresNASDAQ Capital Market Consolidated
PaísUnited Kingdom
Código postalEH12 9DT
Telefone4401313571111
Sitehttps://www.nucana.com/
Código da empresaNCNA
Data de listagemSep 28, 2017
Fundado em1997
Executivos da Empresa
Nome
Nome/Posição
Posição
Ações Detidas
Variação
Mr. Hugh S. Griffith
Mr. Hugh S. Griffith
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
10.60K
--
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
1.33K
+18.87%
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
749.00
+298.40%
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
22.00
--
Dr. Jeffrey D. Bloss, M.D.
Dr. Jeffrey D. Bloss, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Cyrille Leperlier, M.D.
Dr. Cyrille Leperlier, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Christopher F. Brinzey
Mr. Christopher F. Brinzey
Investor Relations
Investor Relations
--
--
Dr. David Harrison, M.D.
Dr. David Harrison, M.D.
Head - Translational Studies
Head - Translational Studies
--
--
Mr. Donald (Don) Munoz
Mr. Donald (Don) Munoz
Chief Financial Officer
Chief Financial Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações Detidas
Variação
Mr. Hugh S. Griffith
Mr. Hugh S. Griffith
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
10.60K
--
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
1.33K
+18.87%
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
749.00
+298.40%
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
22.00
--
Dr. Jeffrey D. Bloss, M.D.
Dr. Jeffrey D. Bloss, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Detalhamento da Receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Acionista
Tempo de atualização: sáb, 22 de mar
Tempo de atualização: sáb, 22 de mar
Estatísticas do Acionista
Tipo
Estatísticas do Acionista
Acionista
Proporção
Sofinnova Investments, Inc
3.51%
Abingworth Management Limited
2.35%
Susquehanna International Group, LLP
0.82%
Schonfeld Strategic Advisors LLC
0.79%
Acadian Asset Management LLC
0.75%
Other
91.78%
Estatísticas do Acionista
Acionista
Proporção
Sofinnova Investments, Inc
3.51%
Abingworth Management Limited
2.35%
Susquehanna International Group, LLP
0.82%
Schonfeld Strategic Advisors LLC
0.79%
Acadian Asset Management LLC
0.75%
Other
91.78%
Tipo
Acionista
Proporção
Venture Capital
5.86%
Investment Advisor
2.08%
Hedge Fund
1.60%
Research Firm
1.12%
Investment Advisor/Hedge Fund
0.78%
Individual Investor
0.22%
Other
88.33%
Instituição Participações
Tempo de atualização: ter, 4 de mar
Tempo de atualização: ter, 4 de mar
Período do Relatório
Nº de instituições
Ações detidas
Proporção
Variação
2025Q1
50
678.81K
11.95%
+387.28K
2024Q4
52
469.91K
11.91%
+42.72K
2024Q3
52
279.81K
7.09%
-247.00K
2024Q2
51
362.89K
15.79%
-1.48K
2024Q1
59
340.51K
14.80%
-343.96K
2023Q4
65
549.25K
25.71%
-320.80K
2023Q3
68
668.24K
31.65%
-112.66K
2023Q2
71
571.34K
27.26%
-362.30K
2023Q1
81
667.89K
31.87%
-504.63K
2022Q4
87
672.60K
32.11%
-559.71K
Ver Mais
Atividade dos Acionistas
Nome
Ações detidas
Proporção
Variação
Chg %
Data
Sofinnova Investments, Inc
199.52K
3.51%
+199.52K
--
Feb 14, 2025
Abingworth Management Limited
133.33K
2.35%
--
--
Dec 31, 2024
Susquehanna International Group, LLP
46.72K
0.82%
+46.72K
--
Dec 31, 2024
Schonfeld Strategic Advisors LLC
45.07K
0.79%
+45.07K
--
Dec 31, 2024
Acadian Asset Management LLC
42.41K
0.75%
+18.79K
+79.54%
Dec 31, 2024
Virtu Americas LLC
40.40K
0.71%
+40.40K
--
Dec 31, 2024
Baillie Gifford & Co.
36.70K
0.65%
--
--
Dec 31, 2024
Citadel Advisors LLC
25.00K
0.44%
+25.00K
--
Dec 31, 2024
Two Sigma Investments, LP
20.99K
0.37%
+20.99K
--
Dec 31, 2024
Glass Jacobson Wealth Advisors
15.00K
0.26%
--
--
Dec 31, 2024
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro das ações
Data de pagamento
Data de ex-dividendo
Sem dados
Desdobramento de Ações
Data
Tipo
Proporção
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Data
Tipo
Proporção
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1